Cellectar Biosciences announced positive 12-month follow-up results from its Phase 2b CLOVER WaM trial of iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia, showing an 83.6% overall response rate and median response duration of 17.8 months. The data meet FDA requirements for accelerated approval and support a confirmatory trial planned for late 2026. The drug showed strong efficacy in patients previously treated with BTK inhibitors, a difficult-to-treat group, and maintained a manageable safety profile. This progress positions iopofosine I 131 as a promising new treatment option for heavily pretreated WM patients with limited alternatives.
Dogecoin's net position delta is increasing despite price consolidation near recent lows, indicating accumulation by investors. A significant drop in profitable holders suggests a potential market bottom, supported by a TD Sequential buy signal point...
Bitcoin has recovered above $62,000 after defending the $58,000 support level twice, signaling a strong buying zone. This rebound was driven by a combination of easing inflation fears, a short squeeze, and a structural shift as European traders move ...
Bitcoin investors currently hold an average unrealized loss of about 20%, with the True Market Mean (TMM) cost basis near $76,700 acting as a key resistance level. This TMM reflects the average acquisition cost of active holders, excluding dormant co...
XRP climbed above $1.14 driven by positive ETF inflows, increased wallet activity, and technical buy signals, signaling renewed accumulation despite ongoing US regulatory uncertainty. Institutional demand remains strong with $6.55 million inflows int...
Wall Street analysts maintain a cautious optimism on Rivian Automotive, assigning it a consensus 'Moderate Buy' rating despite a modest expected price change. Sixteen analysts show mixed opinions with eight buys, five holds, and three sells, and a 12...
